Introduction
============

Understanding how the innate immune response affects the outcome of HIV-1 infection in acute HIV-1 infection will open opportunities for vaccine development that can utilize the innate immunity to enhance viral control with minimal pathogenesis. Dendritic cells (DCs) are particularly important innate immune cells and HIV-1 exploits DCs to enhance infection. Thus, DCs are a critical link between virus, CD4+ T-cells, and CD8+ T-cells. DCs are divided into two broad subsets, myeloid (mDC) and plasmacytoid (pDC), based on phenotype, function, and tissue localization. Although details of these subsets are debated and vary based on species, pDCs are specialized early type 1 interferon-secreting cells that initiate antiviral adaptive immune responses. mDCs differentiate from immature bone marrow (BM)-derived precursors and function as peripheral sentinels by transmitting antigen derived signals to draining lymph nodes (LN). mDCs secrete high levels of interleukin-12 (IL-12) and are key players in amplifying adaptive immune responses \[[@B1]\]. Early immune events during HIV infection are associated with the rate of subsequent disease progression. A role for DCs in controlling HIV-1 replication during primary infection has been difficult to assess, given the difficulties in finding individuals with acute HIV infection. The aim of this study is to study the relationship between DCs number in acute infection and disease progression.

Materials and methods
=====================

Patients
--------

35 patients recently infected with HIV-1 were recruited from an HIV-1-negative high-risk MSM (men who have sex with men) cohort. They were screened every 2 m for HIV-1 infection from October 2006 in the Beijing You'an Hospital \[[@B2]\]. Thirteen of the 35 patients showed rapid progression of HIV-1 disease, with CD4 counts \< 200 cells/ul within 2 y post-infection (CD4 Low Group), while 22/35 cases enrolled in the study maintained a CD4 count higher than 500 cells/ul (CD4 High Group). The progression of early HIV-1 infection can be depicted as six discrete stages, as proposed by Fiebig et al. \[[@B3]\]. All the 35 enrolled patients were in Fiebig stage III. The project was reviewed and approved by the Beijing You'an Hospital Research Ethics Committee, and patients participated in the study following informed consent. Demographic and immunologic characteristics of the patients are reported in Table  [1](#T1){ref-type="table"}.

###### 

Characteristics of patients in this study

   **Patient**   **Age**   **Initial CD4 count**   **Last CD4 count**   **Initial VL**   **VL set point**   **Days from the initial positive point to CD4 \< 200 cells/ul**
  ------------- --------- ----------------------- -------------------- ---------------- ------------------ -----------------------------------------------------------------
        1          22               614                   181               1,558             30,800                                      714
        2          23               296                   159               8,690             24,600                                      459
        3          23               314                   188               53,000            28,400                                      196
        4          25               327                   171              110,000            79,600                                      169
        5          26               415                   117              392,000           153,600                                      153
        6          26               64                    117             26,900,000         714,000                                      172
        7          27               349                   153               61,400            61,400                                      218
        8          29               265                   118              412,000           393,000                                      189
        9          30               610                    72               9,490             7,090                                       755
       10          32               296                   145              400,000            26,000                                      260
       11          34               499                    69              252,000           776,000                                      191
       12          36               285                    53               13,300            13,300                                      345
       13          43               130                   195               16,200            11,940                                      356
       14          22               792                   605               70,200             662                                         ━
       15          23               598                   714               34,000            9,700                                        ━
       16          23               716                   527               14,100            7,210                                        ━
       17          24               805                   827               56,800            35,900                                       ━
       18          24               603                   689               16,400             527                                         ━
       19          25               552                   865               9,170             1,040                                        ━
       20          25               716                   530               14,900            1,940                                        ━
       21          26               678                   622               1,440             3,260                                        ━
       22          26               823                   521               15,000            2,000                                        ━
       23          26               805                   683              258,000            61,200                                       ━
       24          27               640                   619               15,500            4,530                                        ━
       25          29               716                   546               8,780             8,390                                        ━
       26          30               813                   790               9,700             2,300                                        ━
       27          30               745                   589               8,260             1,500                                        ━
       28          31               823                   648                809               200                                         ━
       29          32               678                   546               18,500            5,200                                        ━
       30          32              1148                   1056              1,030              554                                         ━
       31          34               558                   538               26,500            9,700                                        ━
       32          34               835                   546               10,050            1,890                                        ━
       33          37               562                   568               27,600            7,960                                        ━
       34          38               792                   784               70,200            1,312                                        ━
       35          40               720                   639               6,200             3,320                                        ━

VL: viral load.

Flow cytometric analysis
------------------------

To identify DCs, the following antibodies from BD Pharmingen (San Diego, CA, USA) were used: Lin-FITC, CD123-PE and CD11c-APC. At least 200,000 events were acquired for each sample. mDCs were identified as Lin-CD123-CD11c+, while pDCs were Lin-CD123 + CD11c-(Figure  [1](#F1){ref-type="fig"}a). DC counts were calculated as follows, using hemocytometer data for lymphocytes and monocytes and flow cytometry data for DC windows, as described previously \[[@B4],[@B5]\].

![**Comparison of DCs between the three groups. (a)**Analysis of pDC and mDC by flow cytometry, Comparison pDC **(b)** and mDC **(c)** number between normal control and CD4 High Group and CD4 Low Group. Bars indicate median with interquartile range. \*\*\*p \< 0.001, \*\*p \< 0.01, \*p \< 0.05.](1742-6405-11-22-1){#F1}

Absolute blood CD4+ T-cell counts were measured using a FACSCalibur flow cytometer (BD, Franklin Lakes, NJ, USA). Viral load was measured by the Amplicor (Roche Diagnostic Systems, Indianapolis, IN, USA) HIV-1 monitor ultrasensitive method with a detection limit of 40 copies/mL of plasma.

Assays for plasma HIV-1 RNA
---------------------------

Plasma HIV RNA was quantified by real-time PCR (Roche, Germany), a super-sensitive method. The sensitivity of detection of this assay was 40 copies/ml.

Statistical analysis
--------------------

Comparisons were performed using the nonparametric independent sample tests, and all reported p values were two-sided and considered significant at p \< 0.05. All data were analyzed using SPSS statistical software (version 16.0; SPSS, Chicago, IL, USA).

Results
=======

To study the relationship between DCs and disease progression, we compared the pDC and mDC number in Fiebig stage III between the CD4 High, CD4 Low, and normal control groups. We found a higher pDC number in normal controls compared with the CD4 High and CD4 Low groups (Figure  [1](#F1){ref-type="fig"}b). The pDC number between the CD4 High and the CD4 Low groups did not differ significantly (Figure  [1](#F1){ref-type="fig"}b). However, mDCs were significantly lower in the CD4 Low relative to CD4 High and normal controls (Figure  [1](#F1){ref-type="fig"}c). There was no statistically significant difference in the mDC number between the CD4 High and normal controls (Figure  [1](#F1){ref-type="fig"}c). DC numbers were negatively correlated with HIV viral load (Table  [2](#T2){ref-type="table"}).

###### 

Results of spearman correlation analysis

        **Viral load**   **Viral load set point**
  ----- ---------------- --------------------------
  pDC   -0.323\*         -0.350\*
  mDC   -0.233           -0.282

Correlation coefficients (Spearman correlation analysis) are shown.

\*P \< 0.05.

Discussion
==========

Our results are consistent with reports that DCs are markedly reduced in number during acute HIV-1 infection \[[@B6]-[@B9]\], particularly pDCs. The mechanism behind the decline in pDC numbers in acute HIV infection is not clear. It could be because of apoptosis as a direct result of infection \[[@B10],[@B11]\] or mediated by TRAIL and Fas ligand--Fas interactions; it could be a consequence of compromised production of pDC precursors because of bone marrow infection; or it may reflect pDC migration to lymphoid tissues after HIV-induced activation.

mDCs express apolipoprotein B mRNA editing enzyme catalytic polypeptides (APOBECs), proteins that deaminate cytidine to uridine in nascent minus-strand viral DNA, blocking HIV replication \[[@B11],[@B12]\]. Mature mDCs increase APOBECG expression, explaining their relative resistance to HIV-1 infection. mDCs capture and process HIV-1, and present associated antigens to T-cells. Thus, the loss of mDCs may on the one hand decrease APOBECG expression. On the other hand, the loss of mDCs decrease their ability of capture and process HIV-1 and present associated antigen to T cells. Therefore, this may explain why the loss of mDC in acute HIV infection could lead to rapid disease progression.

In conclusion, we found that the loss of mDC rather than pDC from the blood during acute HIV infection is associated with rapid disease progression. However, key questions remain to be answered regarding tissue distribution, development, and functional regulation.
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